Payment overview · 2025
General Payments
$444.65
23 reported records · 7 companies
Healthcare provider profile · identity verified
Benjamin Friedell, MD
Allopathic & Osteopathic Physicians|Family Medicine · ONEONTA, NY · NPI 1912908203
Verified facts
What the public records show
CMS Open Payments records show Benjamin Friedell, MD received $444.65 in general payments during 2025 across 23 reported records.
Novo Nordisk Inc accounted for 23.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 232 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $103.72 | 23.3% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $73.18 | 16.5% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $66.65 | 15.0% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $56.09 | 12.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $56.00 | 12.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.60 | 10.9% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $40.41 | 9.1% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $444.65 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $85.00 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $85.00 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $56.09 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $56.00 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $56.00 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $50.68 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $48.60 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $40.41 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $35.68 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $28.27 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $27.72 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 59 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 232 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 40 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 48 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
59 | 58 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
232 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 513 | 113 |
| Amlodipine Besylate | Amlodipine Besylate | 492 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 396 | 89 |
| Gabapentin | Gabapentin | 311 | 59 |
| Omeprazole | Omeprazole | 255 | 68 |
| Losartan Potassium | Losartan Potassium | 247 | 69 |
| Eliquis | Apixaban | 232 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 223 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 221 | 57 |
| Lisinopril | Lisinopril | 219 | 59 |
| Oxycodone Hcl | Oxycodone Hcl | 219 | 35 |
| Furosemide | Furosemide | 203 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 178 | 42 |
| Sertraline Hcl | Sertraline Hcl | 177 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 170 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 168 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 163 | 46 |
| Famotidine | Famotidine | 158 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 147 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 137 | 38 |
| Finasteride | Finasteride | 133 | 31 |
| Tramadol Hcl | Tramadol Hcl | 133 | 34 |
| Metformin Hcl Er | Metformin Hcl | 130 | 32 |
| Prednisone | Prednisone | 125 | 45 |
| Metformin Hcl | Metformin Hcl | 123 | 28 |
| Trazodone Hcl | Trazodone Hcl | 117 | 24 |
| Atenolol | Atenolol | 110 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 108 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 103 | 24 |
| Ibuprofen | Ibuprofen | 102 | 25 |
| Buspirone Hcl | Buspirone Hcl | 101 | 21 |
| Allopurinol | Allopurinol | 100 | 24 |
| Lorazepam | Lorazepam | 97 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | 16 |
| Glipizide Er | Glipizide | 94 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 25 |
| Pregabalin | Pregabalin | 88 | 18 |
| Potassium Chloride | Potassium Chloride | 81 | 21 |
| Baclofen | Baclofen | 80 | 12 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 78 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 78 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 14 |
| Montelukast Sodium | Montelukast Sodium | 74 | 21 |
| Xarelto | Rivaroxaban | 66 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 15 |
| Simvastatin | Simvastatin | 64 | 20 |
| Carvedilol | Carvedilol | 60 | 16 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 59 | 58 |
| Donepezil Hcl | Donepezil Hcl | 57 | suppressed |
| Ivermectin | Ivermectin | 57 | 35 |
| Myrbetriq | Mirabegron | 57 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 57 | 12 |
| Diazepam | Diazepam | 54 | 12 |
| Mirtazapine | Mirtazapine | 52 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 50 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 15 |
| Latanoprost | Latanoprost | 49 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 48 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 13 |
| Alendronate Sodium | Alendronate Sodium | 47 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | suppressed |
| Trulicity | Dulaglutide | 45 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 43 | suppressed |
| Tradjenta | Linagliptin | 43 | suppressed |
| Meloxicam | Meloxicam | 42 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | suppressed |
| Clonazepam | Clonazepam | 41 | suppressed |
| Ozempic | Semaglutide | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 40 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Cephalexin | Cephalexin | 39 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 39 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 13 |
| Risperidone | Risperidone | 35 | suppressed |
| Torsemide | Torsemide | 33 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Nifedipine Er | Nifedipine | 32 | 12 |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Fentanyl | Fentanyl | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Nystatin | Nystatin | 30 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Budesonide Ec | Budesonide | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Jardiance | Empagliflozin | 23 | suppressed |
| Klor-Con 10 | Potassium Chloride | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Nabumetone | Nabumetone | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Trospium Chloride | Trospium Chloride | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 12 |
| Fosinopril Sodium | Fosinopril Sodium | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 16 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Permethrin | Permethrin | 15 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | 11 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Avonex (4 Pack) | Interferon Beta-1a | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $444.65 · 23 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, BREZTRI, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, NURTEC ODT, Ozempic, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VRAYLAR | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error